EP-2101

N/A

Report date: 2025/02/13 11:06:54
First In Class

Base Information

Drug NameEP-2101
Drug Alias NameTedopiOSE-2101IDM-2101
ClassificationVaccines > Application > Therapeutic vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsNeoplasm MetastasisCarcinoma, Non-Small-Cell LungLung Neoplasms +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[16] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesOse Immunotherapeutics
China Registration ClassN/A

Develop Information

Active CompaniesOse ImmunotherapeuticsChong Kun Dang Pharmaceutical CorpFondazione Ricerca Traslazionale
Inactive CompaniesEpimmune Inc
Active IndicationsNeoplasm MetastasisCarcinoma, Non-Small-Cell LungOvarian Neoplasms +[4] 
Inactive IndicationsLung NeoplasmsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A